drugset
drugset / Trial / NCT02369341

Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

NCT02369341 ↗

Phase 3 Completed 121 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly (over 60 years of age).

Timeline

Start
2015-04-29
Primary completion
2015-06-03
Completion
2015-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluarix Tetra Vaccine — Intramuscular

Indications

influenza